Skip to main content

Rheonix Gets $12.6M in Series A Funding Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rheonix, an Ithaca, NY-based molecular diagnostics startup, has raised $12.6 million in a Series A round of funding.

The firm said that it would use the proceeds to continue development of the Rheonix Chemistry and Reagent Device system, an end-to-end molecular diagnostics instrument that includes raw sample preparation, molecular amplification, and multiplex analysis. It said that the system enables end users to automate new or existing assays using single or multiple raw clinical samples.

"The Rheonix CARD system provides a simple solution for partners who seek to incorporate complex, high-throughput molecular diagnostics into their routine research and development efforts," Rheonix President and CEO Tony Eisenhut said in a statement. "With this funding, we will focus on scaling the Rheonix CARD system to demonstrate the full commercial potential of our platform."

The firm said that the disposable Rheonic CARD technology can be customized for immunoassay, pathogen identification, gene sequence detection, cell-based assays, and other molecular diagnostic applications.

The Series A funding was provided by a syndicate of regional and international firms, which was led by the Cayuga Venture Fund and Bill and Eric Allyn, said Rheonix.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.